Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Prostate Cancer

  Free Subscription


30.12.2018

3 Anticancer Res
1 BMC Cancer
1 Cancer
1 Clin Cancer Res
7 Eur Urol
1 Int J Urol
2 J Clin Oncol
1 J Magn Reson Imaging
1 J Nucl Med
7 J Urol
2 Lancet Oncol
2 Magn Reson Imaging
1 N Engl J Med
1 PLoS One
1 Proc Natl Acad Sci U S A
3 Prostate
2 Ther Adv Urol
4 Urology


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Anticancer Res

  1. NIEDER C, Haukland E, Mannsaker B, Pawinski A, et al
    Initiation of Systemic Therapy During the Last 30 Days of Life in Patients With Metastatic Castration-resistant Prostate Cancer.
    Anticancer Res. 2019;39:335-340.
    PubMed     Text format     Abstract available

  2. MAKINO T, Nakashima K, Iijima M, Kawaguchi S, et al
    Health-related Quality of Life and Toxicity After Single-fraction High-dose-rate Brachytherapy With External Beam Radiotherapy for Localized and Locally Advanced Prostate Cancer.
    Anticancer Res. 2019;39:477-486.
    PubMed     Text format     Abstract available

  3. BASS R, Roberto D, Wang DZ, Cantu FP, et al
    Combining Desmopressin and Docetaxel for the Treatment of Castration-Resistant Prostate Cancer in an Orthotopic Model.
    Anticancer Res. 2019;39:113-118.
    PubMed     Text format     Abstract available


    BMC Cancer

  4. TAKUWA H, Tsuji W, Shintaku M, Yotsumoto F, et al
    Hormone signaling via androgen receptor affects breast cancer and prostate cancer in a male patient: A case report.
    BMC Cancer. 2018;18:1282.
    PubMed     Text format     Abstract available


    Cancer

  5. PRINTZ C
    Early-age drinkers more likely to have high-grade prostate cancer later.
    Cancer. 2019;125:11.
    PubMed     Text format    


    Clin Cancer Res

  6. BHATIA V, Yadav A, Tiwari R, Nigam S, et al
    Epigenetic silencing of miRNA-338-5p and miRNA-421 drives SPINK1-positive prostate cancer.
    Clin Cancer Res. 2018 Dec 26. pii: 1078-0432.CCR-18-3230.
    PubMed     Text format     Abstract available


    Eur Urol

  7. DENTON BT, Hawley ST, Morgan TM
    Optimizing Prostate Cancer Surveillance: Using Data-driven Models for Informed Decision-making.
    Eur Urol. 2018 Dec 18. pii: S0302-2838(18)30965.
    PubMed     Text format    

  8. LOHAUS F, Zophel K, Lock S, Wirth M, et al
    Can Local Ablative Radiotherapy Revert Castration-resistant Prostate Cancer to an Earlier Stage of Disease?
    Eur Urol. 2018 Dec 18. pii: S0302-2838(18)30954.
    PubMed     Text format     Abstract available

  9. MATTA R, Chapple CR, Fisch M, Heidenreich A, et al
    Pelvic Complications After Prostate Cancer Radiation Therapy and Their Management: An International Collaborative Narrative Review.
    Eur Urol. 2018 Dec 17. pii: S0302-2838(18)30962.
    PubMed     Text format     Abstract available

  10. OSTERGREN PB, Murtola TJ, Fode M
    Are Biomarker-driven Inclusion and Symptom Control Endpoints the Future of Phase 3 Trials in Metastatic Castration-resistant Prostate Cancer? Lessons from COMET-2.
    Eur Urol. 2018 Dec 17. pii: S0302-2838(18)31021.
    PubMed     Text format    

  11. GREGUCCI F, Fiorentino A
    Re: Liselotte M.S. Boeve, Maarten C.C.M. Hulshof, Andre N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primar
    Eur Urol. 2018 Dec 24. pii: S0302-2838(18)31030.
    PubMed     Text format    

  12. KHALAF DJ, Sunderland K, Eigl BJ, Kollmannsberger CK, et al
    Health-related Quality of Life for Abiraterone Plus Prednisone Versus Enzalutamide in Patients with Metastatic Castration-resistant Prostate Cancer: Results from a Phase II Randomized Trial.
    Eur Urol. 2018 Dec 24. pii: S0302-2838(18)31020.
    PubMed     Text format     Abstract available

  13. DI LORENZO G, Buonerba C
    Oligometastatic Prostate Cancer: Is it Only a Matter of Perspective?
    Eur Urol. 2018 Dec 24. pii: S0302-2838(18)30998.
    PubMed     Text format     Abstract available


    Int J Urol

  14. INOUE T
    Editorial Comment to Prognostic significance of risk stratification in CHAARTED and LATITUDE studies among Japanese men with de novo metastatic prostate cancer.
    Int J Urol. 2018 Dec 21. doi: 10.1111/iju.13887.
    PubMed     Text format    


    J Clin Oncol

  15. DAVID J, Kamrava M
    Prostate Cancer Radiotherapy: An Evolving Paradigm That Should Also Include High-Dose-Rate Monotherapy.
    J Clin Oncol. 2018 Dec 28:JCO1801482. doi: 10.1200/JCO.18.01482.
    PubMed     Text format    

  16. HALABI S, Dutta S, Tangen CM, Rosenthal M, et al
    Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.
    J Clin Oncol. 2018 Dec 21:JCO1801279. doi: 10.1200/JCO.18.01279.
    PubMed     Text format     Abstract available


    J Magn Reson Imaging

  17. DINIS FERNANDES C, van Houdt PJ, Heijmink SWTPJ, Walraven I, et al
    Quantitative 3T multiparametric MRI of benign and malignant prostatic tissue in patients with and without local recurrent prostate cancer after external-beam radiation therapy.
    J Magn Reson Imaging. 2018 Dec 25. doi: 10.1002/jmri.26581.
    PubMed     Text format     Abstract available


    J Nucl Med

  18. MAURER T, van Leeuwen FWB, Schottelius M, Wester HJ, et al
    Entering the era of molecular-targeted precision surgery in recurrent prostate cancer.
    J Nucl Med. 2018 Dec 20. pii: jnumed.118.221861. doi: 10.2967/jnumed.118.221861.
    PubMed     Text format    


    J Urol

  19. ATALA A
    Re: Diverse AR-V7 Cistromes in Castration-Resistant Prostate Cancer are Governed by HoxB13.
    J Urol. 2019;201:33-34.
    PubMed     Text format    

  20. ATALA A
    Re: Acquisition of Tumorigenic Potential and Therapeutic Resistance in CD133+ Subpopulation of Prostate Cancer Cells Exhibiting Stem-Cell Like Characteristics.
    J Urol. 2019;201:33.
    PubMed     Text format    

  21. TANEJA SS
    Re: Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer.
    J Urol. 2019;201:31.
    PubMed     Text format    

  22. BLOOM JB, Hale GR, Gold SA, Rayn KN, et al
    Predicting Gleason Group Progression for Men on Prostate Cancer Active Surveillance: Role of a Negative Confirmatory Magnetic Resonance Imaging-Ultrasound Fusion Biopsy.
    J Urol. 2019;201:84-90.
    PubMed     Text format     Abstract available

  23. FAIENA I, Salmasi A, Mendhiratta N, Markovic D, et al
    PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    J Urol. 2019;201:91-97.
    PubMed     Text format     Abstract available

  24. BASS R, Fleshner N, Finelli A, Barkin J, et al
    Oncologic and Functional Outcomes of Partial Gland Ablation with High Intensity Focused Ultrasound for Localized Prostate Cancer.
    J Urol. 2019;201:113-119.
    PubMed     Text format     Abstract available

  25. HUANG H, Muscatelli S, Naslund M, Badiyan SN, et al
    Evaluation of Cancer Specific Mortality with Surgery versus Radiation as Primary Therapy for Localized High Grade Prostate Cancer in Men Younger Than 60 Years.
    J Urol. 2019;201:120-128.
    PubMed     Text format     Abstract available


    Lancet Oncol

  26. DENHAM JW, Joseph D, Lamb DS, Spry NA, et al
    Short-term androgen suppression and radiotherapy versus intermediate-term androgen suppression and radiotherapy, with or without zoledronic acid, in men with locally advanced prostate cancer (TROG 03.04 RADAR): 10-year results from a randomised, phase
    Lancet Oncol. 2018 Dec 19. pii: S1470-2045(18)30757.
    PubMed     Text format     Abstract available

  27. SARTOR O
    Androgen deprivation therapy in prostate cancer: new findings and questions for the future.
    Lancet Oncol. 2018 Dec 19. pii: S1470-2045(18)30893.
    PubMed     Text format    


    Magn Reson Imaging

  28. PAPADOPOULOS I, Phillips J, Evans R, Fenn N, et al
    Evaluation of Diffusion Weighted Imaging in the Context of Multi-Parametric MRI of the Prostate in the assessment of suspected low volume prostatic carcinoma.
    Magn Reson Imaging. 2017 Nov 25. pii: S0730-725X(17)30263.
    PubMed     Text format     Abstract available

  29. WARNDAHL BA, Borisch EA, Kawashima A, Riederer SJ, et al
    Conventional vs. reduced field of view diffusion weighted imaging of the prostate: Comparison of image quality, correlation with histology, and inter-reader agreement.
    Magn Reson Imaging. 2017 Nov 2. pii: S0730-725X(17)30237.
    PubMed     Text format     Abstract available


    N Engl J Med

  30. BILL-AXELSON A, Holmberg L, Garmo H, Taari K, et al
    Radical Prostatectomy or Watchful Waiting in Prostate Cancer - 29-Year Follow-up.
    N Engl J Med. 2018;379:2319-2329.
    PubMed     Text format     Abstract available


    PLoS One

  31. CHUNG DY, Goh HJ, Koh DH, Kim MS, et al
    Clinical significance of multiparametric MRI and PSA density as predictors of residual tumor (pT0) following radical prostatectomy for T1a-T1b (incidental) prostate cancer.
    PLoS One. 2018;13:e0210037.
    PubMed     Text format     Abstract available


    Proc Natl Acad Sci U S A

  32. ZADRA G, Ribeiro CF, Chetta P, Ho Y, et al
    Inhibition of de novo lipogenesis targets androgen receptor signaling in castration-resistant prostate cancer.
    Proc Natl Acad Sci U S A. 2018 Dec 21. pii: 1808834116.
    PubMed     Text format     Abstract available


    Prostate

  33. DONADIO JLS, Liu L, Freeman VL, Ekoue DN, et al
    Interaction of NKX3.1 and SELENOP genotype with prostate cancer recurrence.
    Prostate. 2018 Dec 23. doi: 10.1002/pros.23752.
    PubMed     Text format     Abstract available

  34. MATEUS PAM, Kido LA, Silva RS, Cagnon VHA, et al
    Association of anti-inflammatory and antiangiogenic therapies negatively influences prostate cancer progression in TRAMP mice.
    Prostate. 2018 Dec 25. doi: 10.1002/pros.23758.
    PubMed     Text format     Abstract available

  35. TSUMURA H, Ishiyama H, Tabata KI, Sekiguchi A, et al
    Long-term outcomes of combining prostate brachytherapy and metastasis-directed radiotherapy in newly diagnosed oligometastatic prostate cancer: A retrospective cohort study.
    Prostate. 2018 Dec 26. doi: 10.1002/pros.23757.
    PubMed     Text format     Abstract available


    Ther Adv Urol

  36. LEBRET T, Ruffion A, Latorzeff I, Zerbib M, et al
    Criteria for indication and treatment modification in a cohort of patients with prostate cancer treated with hormone therapy.
    Ther Adv Urol. 2018;10:365-376.
    PubMed     Text format     Abstract available

  37. KOSHKIN VS, Small EJ
    Apalutamide in the treatment of castrate-resistant prostate cancer: evidence from clinical trials.
    Ther Adv Urol. 2018;10:445-454.
    PubMed     Text format     Abstract available


    Urology

  38. WU SY, Boreta L, Shinohara K, Nguyen H, et al
    Impact of staging (68)Ga-PSMA-11 PET scans on radiation treatment plans in patients with prostate cancer.
    Urology. 2018 Dec 20. pii: S0090-4295(18)31321.
    PubMed     Text format     Abstract available

  39. BHAT NR, Vetter JM, Andriole GL, Shetty AS, et al
    MRI-Defined PSA Density Significantly Improves the Risk Prediction for Clinically Significant Prostate Cancer on Biopsy.
    Urology. 2018 Dec 20. pii: S0090-4295(18)31324.
    PubMed     Text format     Abstract available

  40. CHANG EM, Punglia RS, Steinberg ML, Raldow AC, et al
    Cost Effectiveness of the Oncotype DX Genomic Prostate Score for Guiding Treatment Decisions in Patients With Early Stage Prostate Cancer.
    Urology. 2018 Dec 20. pii: S0090-4295(18)31334.
    PubMed     Text format     Abstract available

  41. HEIDENREICH A
    WITHDRAWN: Impact of Staging 68Ga-PSMA-11 PET scans on radiation treatment plans in patients with prostate cancer by Thomas Hope et al.
    Urology. 2018 Dec 21. pii: S0090-4295(18)31326.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: